Bob G. Schultz

526 total citations
28 papers, 350 citations indexed

About

Bob G. Schultz is a scholar working on Hematology, Genetics and Epidemiology. According to data from OpenAlex, Bob G. Schultz has authored 28 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Genetics and 4 papers in Epidemiology. Recurrent topics in Bob G. Schultz's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers), Hemophilia Treatment and Research (10 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Bob G. Schultz is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers), Hemophilia Treatment and Research (10 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). Bob G. Schultz collaborates with scholars based in United States, United Kingdom and Japan. Bob G. Schultz's co-authors include Daniel J. Berlau, Daniel R. Touchette, Jessica Tilton, Katie J. Suda, Ali Alobaidi, Alexandra Pérez, Robin S. Turpin, Michael Bullano, Cristina I. Mureşan and Sonya J. Snedecor and has published in prestigious journals such as Blood, Journal of Allergy and Clinical Immunology and Journal of Medical Virology.

In The Last Decade

Bob G. Schultz

20 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bob G. Schultz United States 7 89 75 50 50 42 28 350
Nien-Chen Li United States 7 140 1.6× 122 1.6× 80 1.6× 25 0.5× 12 0.3× 7 438
Bo‐Lin Ho Taiwan 11 65 0.7× 59 0.8× 45 0.9× 50 1.0× 11 0.3× 24 374
Päivi Ruokoniemi Finland 10 122 1.4× 26 0.3× 29 0.6× 34 0.7× 50 1.2× 14 364
Antonio Polini Italy 12 77 0.9× 43 0.6× 76 1.5× 44 0.9× 26 0.6× 19 532
Pasquale Agosti Italy 11 28 0.3× 198 2.6× 84 1.7× 49 1.0× 41 1.0× 31 565
S. De Riu Italy 10 62 0.7× 53 0.7× 87 1.7× 53 1.1× 33 0.8× 17 395
Margaret Scott United Kingdom 9 28 0.3× 98 1.3× 38 0.8× 122 2.4× 13 0.3× 13 376
Caroline Holm Nørgaard Denmark 8 40 0.4× 73 1.0× 62 1.2× 21 0.4× 8 0.2× 10 297

Countries citing papers authored by Bob G. Schultz

Since Specialization
Citations

This map shows the geographic impact of Bob G. Schultz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob G. Schultz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob G. Schultz more than expected).

Fields of papers citing papers by Bob G. Schultz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob G. Schultz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob G. Schultz. The network helps show where Bob G. Schultz may publish in the future.

Co-authorship network of co-authors of Bob G. Schultz

This figure shows the co-authorship network connecting the top 25 collaborators of Bob G. Schultz. A scholar is included among the top collaborators of Bob G. Schultz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob G. Schultz. Bob G. Schultz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Soteres, Daniel, et al.. (2026). Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis. Allergy and Asthma Proceedings. 47(2). 102–111.
2.
Lumry, William R., et al.. (2025). Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years. International Archives of Allergy and Immunology. 187(3). 289–298.
3.
Princic, Nicole, et al.. (2025). Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis. Journal of Comparative Effectiveness Research. 14(4). e240205–e240205.
4.
Craig, Timothy, Alan P. Baptist, John Anderson, et al.. (2025). Hereditary angioedema. Annals of Allergy Asthma & Immunology. 134(4). 465–473.e3. 1 indexed citations
5.
Anderson, John, et al.. (2024). Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study. Allergy and Asthma Proceedings. 45(4). 247–254. 3 indexed citations
6.
Anderson, John, Daniel Soteres, Raffi Tachdjian, et al.. (2024). Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis. Allergy and Asthma Proceedings. 45(6). 426–433. 3 indexed citations
7.
8.
Escobar, Miguel A., et al.. (2023). Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of Medical Economics. 26(1). 574–580. 1 indexed citations
9.
Princic, Nicole, et al.. (2023). Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. Journal of Medical Economics. 26(1). 871–877. 2 indexed citations
10.
Escobar, Miguel A., et al.. (2023). A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Review of Hematology. 16(6). 467–474. 6 indexed citations
11.
Connell, Nathan T., et al.. (2023). Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert Review of Pharmacoeconomics & Outcomes Research. 23(6). 691–699.
12.
Soteres, Daniel, et al.. (2023). Real-World Effectiveness of Lanadelumab in Patients With Normal C1-Inhibitor Hereditary Angioedema: A Multicenter Chart Review. Journal of Allergy and Clinical Immunology. 151(2). AB138–AB138. 2 indexed citations
13.
14.
Jairath, Vipul, et al.. (2022). Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. BMC Gastroenterology. 22(1). 501–501. 3 indexed citations
15.
16.
Schultz, Bob G., et al.. (2021). Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management. Value in Health. 24(4). 522–529. 25 indexed citations
17.
Touchette, Daniel R., Nicole Boyer, Steven J. Atlas, et al.. (2019). PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION. Value in Health. 22. S683–S683.
18.
Schultz, Bob G., et al.. (2018). The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 38(3). 382–389. 89 indexed citations
19.
Schultz, Bob G., et al.. (2018). The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration. 7(1). 5–5. 167 indexed citations
20.
Schultz, Bob G.. (2015). “Online Pharmacy Regulation: How the Ryan Haight Online Pharmacy Consumer Protection Act Can Help Solve an International Problem”. Digital USD (University of San Diego). 16(2). 381. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nien-Chen Li Breakdown of academic impact, for papers by Bo‐Lin Ho Breakdown of academic impact, for papers by Päivi Ruokoniemi Breakdown of academic impact, for papers by Antonio Polini Breakdown of academic impact, for papers by Pasquale Agosti Breakdown of academic impact, for papers by S. De Riu Breakdown of academic impact, for papers by Margaret Scott Breakdown of academic impact, for papers by Caroline Holm Nørgaard
Rankless by CCL
2026